ARS Pharmaceuticals, Inc. (SPRY) Total liabilities 2021–2025
ARS Pharmaceuticals, Inc. (SPRY) total liabilities at each fiscal year-end, per SEC filings.
$213.4MFY2025 · since FY2021: $16.7M → $213.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $213.4M | +126.2% |
| FY2024 | $94.4M | +3786.1% |
| FY2023 | $2.4M | -71.6% |
| FY2022 | $8.5M | -48.7% |
| FY2021 | $16.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY RevenueSPRY Net incomeSPRY Net marginSPRY Gross profitSPRY Gross marginSPRY Operating incomeSPRY Operating marginSPRY Operating cash flowSPRY Free cash flowSPRY Capital expendituresSPRY Return on equitySPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Shareholders’ equitySPRY overview →